Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness (2020)
Journal Article
Ekström, M., Johnson, M. J., Huang, C., & Currow, D. C. (2020). Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness. European respiratory journal, 56(2), Article 1902202. https://doi.org/10.1183/13993003.02202-2019

Copyright ©ERS 2020. BACKGROUND: Chronic breathlessness has devastating consequences. The minimal clinically important difference (MCID) for current intensity has been estimated as 9 mm on a 100-mm visual analogue scale (VAS). We aimed to determine M... Read More about Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness.

Intention-to-treat analyses for randomised controlled trials in hospice/palliative care: the case for analyses to be of people exposed to the intervention. (2019)
Journal Article
Kochovska, S., Huang, C., Johnson, M. J., Agar, M. R., Fallon, M. T., Kaasa, S., …Currow, D. C. (2020). Intention-to-treat analyses for randomised controlled trials in hospice/palliative care: the case for analyses to be of people exposed to the intervention. Journal of pain and symptom management, 59(3), 637-645. https://doi.org/10.1016/j.jpainsymman.2019.10.026

© 2019 American Academy of Hospice and Palliative Medicine Context: Minimizing bias in randomized controlled trials (RCTs) includes intention-to-treat analyses. Hospice/palliative care RCTs are constrained by high attrition unpredictable when consent... Read More about Intention-to-treat analyses for randomised controlled trials in hospice/palliative care: the case for analyses to be of people exposed to the intervention..

Agreement between breathlessness severity and unpleasantness in people with chronic breathlessness: A longitudinal clinical study (2019)
Journal Article
Ekström, M., Williams, M., Johnson, M. J., Huang, C., & Currow, D. C. (2019). Agreement between breathlessness severity and unpleasantness in people with chronic breathlessness: A longitudinal clinical study. Journal of pain and symptom management, 57(4), 715-723.e5. https://doi.org/10.1016/j.jpainsymman.2019.01.001

Context: Chronic breathlessness is a cardinal symptom in cardiopulmonary disease where both overall intensity or severity (S) and unpleasantness (U) are commonly quantified. Objective: We aimed to evaluate agreement between breathlessness severity an... Read More about Agreement between breathlessness severity and unpleasantness in people with chronic breathlessness: A longitudinal clinical study.

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment (2018)
Journal Article
Hardy, J., Skerman, H., Glare, P., Philip, J., Hudson, P., Mitchell, G., …Yates, P. (2018). A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer, 18(1), Article 510. https://doi.org/10.1186/s12885-018-4404-8

© 2018 The Author(s). Background: Nausea/vomiting (N/V) not related to anti-cancer treatment is common in patients with advanced cancer. The standard approach to management is to define a dominant cause, and treat with an antiemetic selected through... Read More about A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment.

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction (2014)
Journal Article
Currow, D. C., Quinn, S., Agar, M., Fazekas, B., Hardy, J., McCaffrey, N., …Clark, K. (2015). Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. Journal of pain and symptom management, 49(5), 814-821. https://doi.org/10.1016/j.jpainsymman.2014.09.013

Context Does octreotide reduce vomiting in cancer-associated bowel obstruction? Objectives To evaluate the net effect of adding octreotide or placebo to standardized therapies on the number of days free of vomiting for populations presenting with vom... Read More about Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.